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Polygenic risk score analyses of symptoms
and treatment response in an
antipsychotic-naive first episode of
psychosis cohort
Marcos Leite Santoro1,2, Vanessa Ota1,2, Simone de Jong3, Cristiano Noto4,5, Leticia M. Spindola2,4, Fernanda Talarico2,4,
Eduardo Gouvea4,5, Sang Hyuck Lee3,6, Patricia Moretti2,4, Charles Curtis3,6, Hamel Patel3,6, Stephen Newhouse 3,6,
Carolina Muniz Carvalho2,4, Ary Gadelha2,4, Quirino Cordeiro4,5, Rodrigo Affonseca Bressan2,4,
Sintia Iole Belangero1,2,4 and Gerome Breen3,6
Abstract
In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical
symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone
treatment (FEP-9W) and (c) with the response to risperidone. We performed a detailed clinical assessment of 60 FEP
patients who were antipsychotic-naive and, again, after nine weeks of standardized treatment with risperidone. After
blood collection and DNA isolation, the samples were genotyped using the Illumina PsychArrayChip and then
imputed. To calculate PRS, we used the latest available GWAS summary statistics from the Psychiatric Genomics
Consortium wave-2 SCZ group as a training set. We used Poisson regression to test association between PRS and
clinical measurements correcting for the four principal components (genotyping). We considered a p-value < 0.0014
(Bonferroni correction) as significant. First, we verified that the schizophrenia PRS was also able to distinguish cases
from controls in this south-eastern Brazilian sample, with a similar variance explained to that seen in Northern
European populations. In addition, within-cases analyses, we found that PRS is significantly correlated with baseline
(pre-treatment) symptoms, as measured by lower clinical global assessment of functioning (−GAF), higher depressive
symptoms and higher scores on a derived excitement factor. After standardized treatment for nine weeks, the
correlation with GAF and the excitement factor disappeared while depressive symptoms became negatively
associated with PRS. We conclude that drug (and other treatments) may confound attempts to understand the
aetiological influence on symptomatology of polygenic risk scores. These results highlight the importance of studying
schizophrenia, and other disorders, pre-treatment to understand the relationship between polygenic risk and
phenotypic features.
Introduction
Schizophrenia (SCZ) is a severe mental disorder
affecting ~1% of the population and is characterized by
the presence of psychosis and other features, such as
negative (i.e., flattened affect and social withdrawal) and
disorganization symptoms (e.g., disorganized speech and
behaviour). Symptomatic and psychosocial deterioration
progress rapidly during the period just after the onset of
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the disorder, termed the first episode of psychosis (FEP)1.
Moreover, reports indicate that brain abnormalities and
cognitive deficits are already present in the FEP1, even
though patients are not affected yet long exposure to
antipsychotics2,3.
SCZ is highly heritable (~80%)4. The most recent
Genome-Wide Association Study (GWAS) for SCZ in the
Psychiatric Genomics Consortium (PGC) wave 2 (PGC2)
tested the association of millions of single-nucleotide
polymorphisms (SNPs) and other types of genetic varia-
tions in ~34,000 cases and ~113,000 controls, and was
particularly successful in uncovering new genes and
pathways for the disorder5. For SCZ (and other psychia-
tric disorders), it is now well accepted that, while no single
variant accounts for a large proportion of cases, thousands
of genetic variants act together to confer the majority of
the genetic risk for the disorder—a polygenic architecture
of risk6,7.
Purcell et al.8 developed and applied the method pro-
posed by Wray et al.7 to calculate a polygenic risk score
(PRS) explaining 2–3% of variance in SCZ case-control
status7,8. With the large increases in sample size enabled
by international GWAS consortia, the SCZ PRS has
become more powerful. Using the PGC2 SCZ GWAS as a
training sample5, predictive SNPs achieving a nominal p-
value threshold can be selected and the PRS of an indi-
vidual in independent sample can be calculated. More
specifically, the effect size estimated in the training sample
for each SNP’s risk allele is multiplied by the number of
risk alleles present in an individual. This is then summed
across all variants selected in the genome to yield a PRS
for every individual in a training sample8,9.
Such a PRS has a much larger effect size than any single
genetic variant and does not need a large sample size for
the target sample as long as it is estimated from a very
large training sample9. The SCZ PRS represents a genetic
estimate of liability to the disorder and is a normally
distributed quantitative trait that can be applied in many
ways. For SCZ, the PRS has been correlated with quan-
titative variables, such as severity of symptoms10 and
prefrontal activity11. For bipolar disorder, PRS has been
correlated to function and brain structures in individuals
at risk12,13, and, for depression, it has been correlated with
the reduction of the cortical volume in specific regions14.
A recent paper by Vassos et al.15 reported that SCZ PRS is
associated with diagnosis inFEP patients. One recent
study reported a positive correlation between SCZ PRS
and negative symptoms in an (unaffected) adolescent
population cohort16. Recently, another article found
positive associations between a genetic (rather than
polygenic) risk score generated with 84 SNPs with positive
and negative symptoms at the FEP, but not after
treatment17.
No study, to our knowledge, has examined the corre-
lation of PRS with the untreated symptom profile of SCZ
patients or the response to treatment in FEP patients. In
this study, we test if the SCZ PRS is correlated with
symptomatology, severity and response to antipsychotics




We enrolled patients with FEP at admission to the
Centro de Atenção Integral a Saúde Mental (CAISM), São
Paulo. The study protocol was designed to address the
acute but temporary lack of capacity in FEP patients at
admission. When a patient was admitted meeting the
inclusion criteria (below), medical staff explained the
study to family members, provided printed information
sheets and, if agreeing, families then signed a written
informed consultee consent with the assent of the patient.
At the follow-up assessment, the patients were directly
consented into the study, provided they had capacity. If
subjects lacked capacity at the follow-up assessment,
consent was taken at a later stage when capacity was
regained. The local Research Ethics Committee of Uni-
versidade Federal de São Paulo (CEP-UNIFESP 0603/10)
and the national Brazilian Ethics Committee (CONEP-
CAAE 33148114.6.0000.5505, CAAE
48242015.9.0000.5505) approved the research protocol.
Longitudinal cohort of FEP patients
Our cohort of antipsychotic-naiveFEP patients includes
154 subjects recruited from a psychiatric emergency unit
in São Paulo (Brazil). The diagnosis of a psychotic dis-
order was established by trained psychiatrists using
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria, using the Structured
Clinical Interview for DSM-IV (SCID-I). Inclusion criteria
were aged between 16 and 40 years without previous
history of antipsychotic medication and with confirmed
non-affective psychosis (SCZ, schizophreniform disorder
or brief psychosis disorder diagnosis) after two months of
treatment. Prior or current treatment with benzodiaze-
pines was allowed. Patients with psychotic episodes due to
a general medical condition, substance-induced psychotic
disorder, intellectual disability, major depressive disorder
or bipolar disorder were excluded.
A total of 60 patients met criteria for antipsychotic-
naive FEP after the follow-up (FEP, N= 60). These
patients were assessed at baseline and followed up for
9.03 ± 2.76 weeks of risperidone treatment. Four patients
were taking benzodiazepines and one clonazepam, at
baseline. During follow-up, besides risperidone, 12 were
taking clonazepam and 7 mood stabilizers.
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The healthy control group (N= 60) comprised age-
gender-and-ethnicity-matched volunteers with no first-
degree family history of psychotic disorders, who were
evaluated by trained psychiatrists using a modified SCID-I
to ensure no current or previous psychiatric diagnoses.
Peripheral blood samples were collected in EDTA tubes at
baseline and follow-up for patients and after psychiatric
interview for controls.
Clinical assessments
All psychiatrists had the same training at the “Programa
de Esquizofrenia da UNIFESP” and the FEP patients were
always assessed by the same psychiatrist at both time
points for the following scales: (a) PANSS (Positive and
Negative Syndrome Scale), (b) CGI (Clinical Global
Impression Scale)18, (c) GAF (Global Assessment of
Functioning Scale), (d) CDSS (Calgary Depression Scale
for SCZ)19.
Symptom clusters (negative, positive, disorganization,
excited and anxiety/depression) from the PANSS items20
were calculated using the algorithm from a previous study
in a Brazilian population21. For more information about
each symptom cluster, see Supplementary Table S1.
Response to treatment was defined as a > 50% reduction
in baseline PANSS total score22. GAF is the only scale
where higher values represent less impairment; thus we
transformed to them to negative values (referred to as
−GAF).
DNA isolation
Whole blood was collected into EDTA tubes, and
genomic DNA isolation was performed using the Gentra
Puregene Kit (Qiagen) according to the manufacturer’s
protocol.
Genomic arrays
The genotyping was performed at King’s College Lon-
don using the Infinium PsychArray-24 BeadChip (Illu-
mina) with a GWAS core backbone (~590 K markers) and
specific content from the Psychiatric Genomics Con-
sortium: https://www.med.unc.edu/pgc/psychchip.
Quality control and imputation
For the quality control (QC) parameters, we removed
SNPs with a minor allele frequency (MAF) < 1%, Locus
missingness > 10% or Hardy–Weinberg disequilibrium
significance < 0.00001. We also excluded individuals with
missingness > 10% and an estimation of identity-by-des-
cent > 0.12. Genotype imputation was performed using
the https://imputation.sanger.ac.uk using as Reference
Panel the Haplotype Reference Consortium (release 1)
with 32,488 samples (39M sites) and the Pre-phasing
algorithm SHAPEIT2. After post-imputation QC, using
the same parameters as above, ~ 9M SNPs were analysed.
Polygenic risk scores
For more information about how the scores are calcu-
lated, please see the Supplementary Material of Purcell
et al.8. To generate the PRS we used the PRSice software
(www.PRSice.info) default options. The SCZ sample from
PGC2 (downloaded from https://www.med.unc.edu/pgc)
was used as the training sample and our imputed geno-
typing sample as the target. The PGC2 SCZ PRS is gen-
erated from many individual samples that may represent
more chronic and severe SCZ, such as patients on clo-
zapine. This means the PGC PRS represents a powerful
tool to understand the influence of SCZ risk on clinically
important symptom dimensions pre-treatment. We per-
formed P-value-informed clumping with a cutoff of r2=
0.1 using a 250-kb window and calculated scores per
individual for multiple p-threshold (ranging from 0.0001
to 0.5 with increments of 0.00005) including or excluding
the MHC (major histocompatibility complex) region on
chromosome 6, which has a complex linkage dis-
equilibrium structure. Given that our sample is sampled
from an admixed south eastern Brazilian population, we
carefully assessed population stratification and used the
first four components generated by plink1.9 software were
used as covariables. Posteriorly, PRSice runs a regression
to find the best p-threshold based on the explained var-
iance (Nagelkerke’s pseudo-r2 correlation) and in our case
gave PRSs based on the most FEP case-control variance
explained.
Statistical analysis
We used R for all statistical analysis. With the PRSs
calculated for the case-control comparison, we used a
generalized linear model to test PRS associations assum-
ing a Poisson distribution (Poisson regression), which is
more suitable for ordinal variables (such as psychiatric
scales), using clinical traits as the dependent variable and
the best p-threshold PRS with the first four principal
components as the independent variables and covariates.
As clinical outcome variables, we considered, for both
time points, GAF score, total CGI score, total PANSS
scores and the five PANSS dimension clusters suggested
by Wallwork et al.20 and validated by Higuchi et al.21 in
the Brazilian population. GAF values were transformed to
negative values (−GAF), so all clinical variables were
easily compared, with high values meaning high sympto-
matology. We defined as outliers those observations lying
beyond 1.5 times the ‘Inter Quartile Range’ - the differ-
ence between 75th and 25th quartiles.
We applied the Bonferroni correction for multiple
comparisons (number of psychiatric scales tested N= 36),
considering as significant a p-value < 0.0014 (0.05/36). As
the Brazilian population is known to be a highly admix-
ture population, we first plotted case and controls prin-
cipal components to check if they have similar
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background and then we did a sensitivity analysis con-
sidering only full European ancestry cases.
Using the residuals from the PRS with principal com-
ponents, we tested if the available demographics could be
potential confounders. Further, we tested if response to
risperidone overall or within subtypes of FEP included in
our study (SCZ or schizophreniform) was associated with
SCZ PRS. First, we tested the change in symptoms from
baseline to the follow-up and if the subtype of FEP was
associated with the PRS using a Poisson regression. Sec-
ond, we tested the correlation between the change in total
PANSS and PRS using a Pearson correlation. Finally, we
verified if there was an association of clonazepam or
mood stabilizers with CDSS, CGI, GAF and PANSS
symptoms that could be affecting the results.
Results
Table 1 shows the clinical and demographic character-
istics of the participants. Smoking rates significantly
higher in cases than in controls. Patients showed
improvement after nine weeks of risperidone treatment
for all scales and symptom clusters, except for PANSS
negative. Figure S8 shows a heatmap of the correlations
among the tested clinical variables, demonstrating, a high
correlation between PANSS depressive factor and CDSS,
and between GAF and most clinical variables. Table S2
and S3 shows that there are no associations between
demographics with either PRS or clinical variables.
Brazilian admixture sample
Cases and controls showed similar principal compo-
nents structure, and when analysing only the European
ancestry individuals (self-declared and consistent with the
genetic estimates) the direction and magnitude of asso-
ciations remained the same (Table S5 and Figures S1, S7).
Polygenic risk
The number of independent SNPs analysed for each
threshold and cohort is described in Supplementary Table
S4. With or without the MHC region, results were similar;
thus, we carried on including the MHC region to increase
the number of analysed SNPs and, consequently, the
power of our analysis. The PRS was significantly different
between cases and controls (Fig. 1) with a best p-threshold
of 0.0112 (NSNPs= 21,622) and an explained variance of
0.19 (Nagelkerk’s pseudo-r2). Figure S7 shows the normal
Table 1 Clinical and demographic characteristics of the participants in this study
Variable Healthy controls
(N=59)
Antipsychotic-naive FEP (N=60) FEP after treatment
(N=60)
p-value
Gender (%) M:34 (57.6%) M:40 (66.7%) 0.309
Age in years; mean (SD) 25.97 (7.48) 25.63 (7.46) 0.808
Currently smoking (%) N= 2 (3.6%) N= 12 (23.5%) 0.002
Family history of psychosis (%) N= 23 (50%)
Cannabis use (%) N= 18 (52.9%)
Other drugs use (%)* N= 13 (41.9%)
Family income in US$/month (SD) 870.59 (792.31)
BMI in kg/m2 23.58 (3.78)
PANSS negative; mean (SD) 27.37 (10.51) 25.02 (9.28) 0.127
PANSS disorganization/cognition; mean
(SD)
26.96 (8.58) 19.91 (6.22) 5.029 × 10-8
PANSS excitement; mean (SD) 24.69 (9.09) 13.22 (5.62) 7.84 × 10-14
PANSS positive; mean (SD) 34.75 (7.32) 21.23 (9.52) 2.46 × 10-13
PANSS depression/anxiety; mean (SD) 24.24 (8.79) 18.11 (7.85) 2.97 × 10-5
PANSS total 94.55 (20.94) 68.21 (20.31) 1.71 × 10-10
GAF; mean (SD) 31.21 (10.52) 55.47 (16.61) 1.34 × 10-11
CGI; mean (SD) 4.83 (0.72) 3.35 (1.26) 1.77 × 10−11
CDSS; mean (SD) 4.64 (5.04) 2.48 (4.27) 0.007
M male, SD standard deviation, FEP first-episode psychosis, PANSS Positive and Negative Syndrome Scale, CGI Clinical Global Impression Scale, GAF Global Assessment
of Functioning Scale, CDSS Calgary Depression Scale for Schizophrenia
*Drugs including cocaine, sedatives, stimulants, hallucinogens, opioids and gases
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distribution of the PRS for cases and controls, and Figure
S10 shows the odds ratio (OR) of psychosis for quantiles
of PRS.
PRS and clinical variables relation
At baseline (antipsychotic naive FEP), we find a positive
association PRS with the PANSS excitement factor (five-
factor model) (B= 566.7; p-value= 0.0003) and a trend
for association with –GAF (B= 436.1; p-value= 0.003).
PRS showed a positively trend for depressive symptoms at
baseline (CDSS total: B= 1042.3; p-value= 0.0039) but
became significantly negatively associated with depressive
symptoms after risperidone treatment (CDSS total: B=
−1800.2; p-value= 0.0004). The results are summarized
in Table 2 and Figures S2–S4.
Looking at response to risperidone, we analysed the five
PANSS factors and other scales, we observed a positive
association for ΔCDSS (B= 717; p-value= 0.0006) (Table
3). However, considering the total PANSS, there was no
correlation between Δtotal PANSS and PRS (t= 0;62633,
df= 49; p-value= 0.534; r= 0.089). Although a border-
line association was observed between PANSS-excitement
at the follow-up and mood stabilizer use (N= 7), the
relationship between PRS and PANSS-excitement
remained not significant even adding this as a covariate
(B=−110, p= 0.94).
Within FEP subtypes, depressive symptoms (CDSS)
were positively associated with PRS in both FEP subtypes
when analysed separately at baseline (Bschizophrenia=
1746.1; pschizophrenia= 0.002; Bschizophreniform=2660.0;
pschizophreniform=0.036), while PANSS excitement and
−GAF was associated only in the schizophreniform sub-
group (B= 1393.3; p= 9 × 10-5 and B=−1449.1; p=
1.3 × 10-4, respectively) (Table 4, Supplementary Figs S5
and S6).
Given the different pattern of association between
depressive symptoms (CDSS) and PRS at the baseline
(positive association) and after treatment (negative asso-
ciation), we generated a trajectory plot to visualize each
individual symptom in both time points (Figure S9). We
can note that those individuals with high PRS tend to
show a decrease in their depressive symptoms after ris-
peridone treatment, while those with low PRS tend to
maintain or increase their level of depressive symptoms.
Discussion
In this study, we demonstrate for the first time that the
SCZ PRS is associated with different clinical symptoms
during the pre-treatment stage of FEP. Although recently
Sengupta et al.17 reported positive associations between
PRS and clinical variables and FEP, it is important to note
that our methods were different in many aspects; we
included (1) only non-affective FEP, (2) only antipsychotic
naive FEP, (3) applied a standardized treatment (risper-
idone) and (4) calculated the PRS using more than 21 K
SNPs (compared with 84 used by them). Specifically, in
pre-treatment FEP patients, we identified a positive cor-
relation of PRS with depressive symptoms (CDSS total),
excitement symptoms (PANSS-excitement factor) and
with Global Assessment of Functioning (−GAF). After
standardized treatment for 9 weeks with risperidone, we
observed no positive association for these or other clinical
measurements, but a negative correlation with PRS
emerges for both CDSS and PANSS depressive/anxiety
factor. Concordant with this, Sengupta et al.17 observed
similar results for CDSS, although not reaching statistical
significance, probably because of the lower power of
including only 84 SNPs in the genetic risk score. These
results suggest the potential aetiological importance of
depression (and anxiety) in SCZ. In sensitivity analyses,
we found that observed baseline positive correlation with
PANSS excitement and –GAF was driven by the subgroup
composed by individuals with schizophreniform or brief
psychosis disorder diagnoses (Table 4), while the positive
correlation of SCZ PRS with depressive symptoms was
present irrespective of diagnostic group.
Looking at treatment response, we found that pre-
treatment baseline to post-treatment follow-up changes
for PANSS excitement (ΔPANSS excitement) and CDSS
(ΔCDSS) were also positively correlated with SCZ PRS
(Table 3), suggesting that patients with a higher PRS tend
to show more improvement in symptoms after treatment
(Figure S9) and that those with lower PRS have increased
depressive symptoms. It is well known that some patients
may have an increase in depressive symptoms once
positive symptoms remit, being recognised as a clinical
disorder (ICD F20.4= post-SCZ depression). However,
Fig. 1 Graph from PRSice showing the explained variance (y-axis) for
each p-threshold (x-axis) to identify cases and controls for our sample
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no study, to our knowledge has yet evaluated the relation
between PRS and post-SCZ depression. Lastly, it is
important to note that although we detected differences in
these two symptom dimensions, we do not observe an
association between total PANSS improvement (ΔPANSS
total) and PRS SCZ. Taken together, these results suggest
that FEP patients who present with higher depressive and
excitement symptoms and/or who show reduction in
these dimensions after treatment with risperidone have a
significantly higher genetic risk for SCZ (as estimated by
PRS).
It is important to note that all previous studies of PRS
and symptoms in SCZ used different study designs and,
moreover, their samples were composed of patients under
antipsychotic treatment. Vassos et al.15 suggested that the
different subgroups in theirFEP sample (specifically non-
Table 2 PRS correlation with clinical variable during the baseline and the follow-up
Time Clinical variable N B p-value
Baseline (antipsychotic naive FEP) CGI 50 72.8 0.8436
a−GAF 48 436.1 0.0030
aCDSS total 51 1042.3 0.0039
PANSS total 53 38.1 0.6390
aPANSS positive 53 400.0 0.0278
PANSS negative 53 −205.6 0.3048
PANSS general psychopathology 53 −20.2 0.8886
Five-factor model21 PANSS negative 53 −168.2 0.2655
PANSS disorganization/cognition 53 −32.9 0.8281
bPANSS excitement 53 566.7 0.0003
PANSS positive 53 27.1 0.8382
PANSS depression/anxiety 53 −112.8 0.4761
Follow-up (9 weeks treated with risperidone) CGI 51 −137.4 0.7588
−GAF 53 −132.8 0.2281
bCDSS total 53 −1800.2 0.0004
PANSS total 54 −113.4 0.2215
PANSS positive 56 277.3 0.3141
PANSS negative 56 −358.3 0.0894
PANSS general psychopathology 54 −287.9 0.1140
Five-factor model21 PANSS negative 56 −180.6 0.2329
PANSS disorganization/cognition 56 −75.8 0.6608
PANSS excitement 56 216.4 0.3048
PANSS positive 56 10.0 0.9522
bPANSS depression/anxiety 55 −575.0 0.0013
PANSS Positive and Negative Syndrome Scale, CGI Clinical Global Impression Scale, GAF Global Assessment of Functioning Scale, CDSS Calgary Depression Scale for
Schizophrenia
aSignificant p-values without Bonferroni correction
bSignificant p-values with Bonferroni correction
Table 3 PRS association with clinical variables of
risperidone treatment response
Clinical variables (follow-up - baseline) N B p-value
Five-factor model21 ΔPANSS negative 53 −71.6 0.5948
ΔPANSS positive 53 −74.5 0.6824
ΔPANSS disorganization 53 −35.3 0.8493
ΔPANSS depression/anxiety 52 222.7 0.1173
aΔPANSS excitement 53 473.5 0.0034
bΔCDSS 49 717.2 0.0006
Delta was calculated subtracting the measures of follow-up minus the baseline
aSignificant p-values without Bonferroni correction
bSignificant p-values with Bonferroni correction
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affective versus affective psychosis) have different PRS,
whereas our sample included only non-affective FEP.
Additionally, we did not observe overall PRS differences
between our FEP subgroups. In addition, a recent study,
within a large population cohort of adolescents, found an
association between PRS and negative symptoms but not
with depressive symptoms16.
One strength of our study is that all patients were
antipsychotic-naïve at the baseline and received the same
treatment for approximately the same time. Our study
also has several limitations, primary amongst which is that
our FEP sample size is small (N= 60). The treatment
used, risperidone, has been shown to be beneficial as an
augmentation therapy in MDD patients who have a high-
risk for suicide23 and in patients who were treatment-
refractory for MDD24. However, it is a unique longitudinal
sample of antipsychotic naïve FEP individuals. We will
increase this sample in the future but at the moment it
represents a (near) unique resource. Despite these lim-
itations, this is the first study to explore PRS before
standardized treatment initiation in the FEP as well as the
change in symptoms after a sufficient time period in
which to observe response to treatment.
Our results suggest that drugs and other treatments
may confound our understanding of the influence of PRS
on symptomatology due to their effects on specific
symptoms. We expect that future studies will explore
additional clinical dimensions, taking into account the
response to different antipsychotics, while increasing the
sample size of treatment naïve patients analysed to have
more statistical power. In conclusion, we have shown that
that excitement and depressive symptoms are positively
associated to SCZ-PRS during FEP pre-treatment but not
after risperidone treatment and that increased SCZ-PRS is
associated with the risperidone induced improvement of
both depressive and excitement symptoms.
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Table 4 Association between the statistically significant clinical variables with PRS splitting the FEP patients into FEP
subtypes according to the follow-up diagnosis
Subtype Clinical variable Timepoint N B p-value
Schizophreniform a−GAF Baseline 9 −1449.1 0.00013
bCDSS Baseline 9 2660.0 0.03594
CDSS Follow-up 10 −2323.7 0.20033
aPANSS excitement Baseline 11 1393.3 0.00009
PANSS depression/anxiety Follow-up 10 −622.3 0.15126
bΔPANSS excitement Baseline - follow-up 11 877.8 0.02002
ΔCDSS Baseline - follow-up 9 497.4 0.30954
Schizophrenia only −GAF Baseline 27 300.3 0.21538
bCDSS Baseline 29 1746.1 0.00217
aCDSS Follow-up 27 −3739.3 0.00009
PANSS excitement Baseline 29 206.5 0.39645
aPANSS depression/anxiety Follow-up 29 −1286.2 0.00002
ΔPANSS excitement Baseline - follow-up 29 324.9 0.19858
aΔCDSS Baseline - follow-up 27 1358.7 0.00002
aSignificant p-values with Bonferroni correction
bSignificant p-values without Bonferroni correction
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